Open AccessUrine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates
Author(s) -
Carlos R. Franco Palacios,
John C. Lieske,
Hani M. Wadei,
Andrew D. Rule,
Fernando C. Fervenza,
Nikolay Voskoboev,
Vesna D. Garovic,
Ladan Zand,
Mark D. Stegall,
Fernando G. Cosio,
Hatem Amer
Publication year - 2013
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3182977ab1
Subject(s) - supar , medicine , proteinuria , focal segmental glomerulosclerosis , membranous nephropathy , urology , gastroenterology , kidney transplantation , albuminuria , urokinase receptor , creatinine , nephrotic syndrome , urinary system , kidney disease , kidney , urokinase
Recently, serum soluble urokinase receptor (suPAR) has been proposed as a cause of two thirds of cases of focal segmental glomerulosclerosis (FSGS). It was noted to be uniquely elevated in cases of primary FSGS, with higher levels noted in cases that recurred after transplantation. It is also suggested as a possible target and marker of therapy.